Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ca-DTPA and Zn-DTPA for Gadolinium Deposition Disease
NCT02947022Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pentetate calcium trisodium, zinc diethylenetriaminepentaacetic acid in Gadolinium deposition disease (GDD), sponsored by University of North Carolina at Chapel Hill. Started Oct 2016; status: terminated.
02
Drugs
pentetate calcium trisodiumzinc diethylenetriaminepentaacetic acid
03
Conditions
Gadolinium deposition disease (GDD)
Beyond the preview
Go deeper on NCT02947022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947022.